ERβ expression and breast cancer risk prediction for women with atypias

Tina J Hieken, Jodi Carter, John R Hawse, Tanya L. Hoskin, Melanie Bois, Marlene Frost, Lynn C. Hartmann, Derek C Radisky, Daniel W Visscher, Amy C Degnim

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Epithelium and a putative tumor suppressor. Atypical hyperplasia substantially increases breast cancer risk, but identification of biomarkers to further improve risk stratification is needed. We evaluated ERβ expression in breast tissues from women with atypical hyperplasia and association with subsequent breast cancer risk. ERβ expression was examined by immunohistochemistry in a well-characterized 171-women cohort with atypical hyperplasia diagnosed 1967-1991. Nuclear ERβ percent and intensity was scored in the atypia and adjacent normal lobules. An ERβ sum score (percent + intensity) was calculated and grouped as low, moderate, or high. Competing risks regression was used to assess associations of ERβ expression with breast cancer risk. After 15-year median follow-up, 36 women developed breast cancer. ERβ expression was lower in atypia lobules in than normal lobules, by percent staining and intensity (both P <0.001). Higher ERβ expression in the atypia or normal lobules, evaluated by percent staining, intensity or sum score, decreased the risk of subsequent breast cancer by 2-fold (P = 0.04) and 2.5-fold (P = 0.006). High normal lobule ERβ expression conferred the strongest protective effect in premenopausal women: the 20-year cumulative incidence of breast cancer was 0% for women younger than 45 years with high versus 31% for low-moderate ERβ expression (P = 0.0008). High ERβ expression was associated with a significantly decreased risk of breast cancer in women with atypical hyperplasia. These data suggest that ERβ may be a useful biomarker for risk stratification and a novel therapeutic target for breast cancer risk reduction.

Original languageEnglish (US)
Pages (from-to)1084-1092
Number of pages9
JournalCancer Prevention Research
Volume8
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Breast Neoplasms
Hyperplasia
Biomarkers
Staining and Labeling
Risk Reduction Behavior
Breast
Epithelium
Immunohistochemistry
Incidence
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

ERβ expression and breast cancer risk prediction for women with atypias. / Hieken, Tina J; Carter, Jodi; Hawse, John R; Hoskin, Tanya L.; Bois, Melanie; Frost, Marlene; Hartmann, Lynn C.; Radisky, Derek C; Visscher, Daniel W; Degnim, Amy C.

In: Cancer Prevention Research, Vol. 8, No. 11, 01.11.2015, p. 1084-1092.

Research output: Contribution to journalArticle

@article{27c4b834a0b948788dcd6fbdb6ef10eb,
title = "ERβ expression and breast cancer risk prediction for women with atypias",
abstract = "Epithelium and a putative tumor suppressor. Atypical hyperplasia substantially increases breast cancer risk, but identification of biomarkers to further improve risk stratification is needed. We evaluated ERβ expression in breast tissues from women with atypical hyperplasia and association with subsequent breast cancer risk. ERβ expression was examined by immunohistochemistry in a well-characterized 171-women cohort with atypical hyperplasia diagnosed 1967-1991. Nuclear ERβ percent and intensity was scored in the atypia and adjacent normal lobules. An ERβ sum score (percent + intensity) was calculated and grouped as low, moderate, or high. Competing risks regression was used to assess associations of ERβ expression with breast cancer risk. After 15-year median follow-up, 36 women developed breast cancer. ERβ expression was lower in atypia lobules in than normal lobules, by percent staining and intensity (both P <0.001). Higher ERβ expression in the atypia or normal lobules, evaluated by percent staining, intensity or sum score, decreased the risk of subsequent breast cancer by 2-fold (P = 0.04) and 2.5-fold (P = 0.006). High normal lobule ERβ expression conferred the strongest protective effect in premenopausal women: the 20-year cumulative incidence of breast cancer was 0{\%} for women younger than 45 years with high versus 31{\%} for low-moderate ERβ expression (P = 0.0008). High ERβ expression was associated with a significantly decreased risk of breast cancer in women with atypical hyperplasia. These data suggest that ERβ may be a useful biomarker for risk stratification and a novel therapeutic target for breast cancer risk reduction.",
author = "Hieken, {Tina J} and Jodi Carter and Hawse, {John R} and Hoskin, {Tanya L.} and Melanie Bois and Marlene Frost and Hartmann, {Lynn C.} and Radisky, {Derek C} and Visscher, {Daniel W} and Degnim, {Amy C}",
year = "2015",
month = "11",
day = "1",
doi = "10.1158/1940-6207.CAPR-15-0198",
language = "English (US)",
volume = "8",
pages = "1084--1092",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - ERβ expression and breast cancer risk prediction for women with atypias

AU - Hieken, Tina J

AU - Carter, Jodi

AU - Hawse, John R

AU - Hoskin, Tanya L.

AU - Bois, Melanie

AU - Frost, Marlene

AU - Hartmann, Lynn C.

AU - Radisky, Derek C

AU - Visscher, Daniel W

AU - Degnim, Amy C

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Epithelium and a putative tumor suppressor. Atypical hyperplasia substantially increases breast cancer risk, but identification of biomarkers to further improve risk stratification is needed. We evaluated ERβ expression in breast tissues from women with atypical hyperplasia and association with subsequent breast cancer risk. ERβ expression was examined by immunohistochemistry in a well-characterized 171-women cohort with atypical hyperplasia diagnosed 1967-1991. Nuclear ERβ percent and intensity was scored in the atypia and adjacent normal lobules. An ERβ sum score (percent + intensity) was calculated and grouped as low, moderate, or high. Competing risks regression was used to assess associations of ERβ expression with breast cancer risk. After 15-year median follow-up, 36 women developed breast cancer. ERβ expression was lower in atypia lobules in than normal lobules, by percent staining and intensity (both P <0.001). Higher ERβ expression in the atypia or normal lobules, evaluated by percent staining, intensity or sum score, decreased the risk of subsequent breast cancer by 2-fold (P = 0.04) and 2.5-fold (P = 0.006). High normal lobule ERβ expression conferred the strongest protective effect in premenopausal women: the 20-year cumulative incidence of breast cancer was 0% for women younger than 45 years with high versus 31% for low-moderate ERβ expression (P = 0.0008). High ERβ expression was associated with a significantly decreased risk of breast cancer in women with atypical hyperplasia. These data suggest that ERβ may be a useful biomarker for risk stratification and a novel therapeutic target for breast cancer risk reduction.

AB - Epithelium and a putative tumor suppressor. Atypical hyperplasia substantially increases breast cancer risk, but identification of biomarkers to further improve risk stratification is needed. We evaluated ERβ expression in breast tissues from women with atypical hyperplasia and association with subsequent breast cancer risk. ERβ expression was examined by immunohistochemistry in a well-characterized 171-women cohort with atypical hyperplasia diagnosed 1967-1991. Nuclear ERβ percent and intensity was scored in the atypia and adjacent normal lobules. An ERβ sum score (percent + intensity) was calculated and grouped as low, moderate, or high. Competing risks regression was used to assess associations of ERβ expression with breast cancer risk. After 15-year median follow-up, 36 women developed breast cancer. ERβ expression was lower in atypia lobules in than normal lobules, by percent staining and intensity (both P <0.001). Higher ERβ expression in the atypia or normal lobules, evaluated by percent staining, intensity or sum score, decreased the risk of subsequent breast cancer by 2-fold (P = 0.04) and 2.5-fold (P = 0.006). High normal lobule ERβ expression conferred the strongest protective effect in premenopausal women: the 20-year cumulative incidence of breast cancer was 0% for women younger than 45 years with high versus 31% for low-moderate ERβ expression (P = 0.0008). High ERβ expression was associated with a significantly decreased risk of breast cancer in women with atypical hyperplasia. These data suggest that ERβ may be a useful biomarker for risk stratification and a novel therapeutic target for breast cancer risk reduction.

UR - http://www.scopus.com/inward/record.url?scp=84946121031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946121031&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-15-0198

DO - 10.1158/1940-6207.CAPR-15-0198

M3 - Article

C2 - 26276747

AN - SCOPUS:84946121031

VL - 8

SP - 1084

EP - 1092

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 11

ER -